Arena Pharmaceuticals (ARNA) Falls Ahead of FDA Decision
Tweet Send to a Friend
Up)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) is seeing notable pressure this morning ahead of the important FDA decision on obesity drug Lorcaserin.
Shares last traded at $8.20, down over 7 percent from the close.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Shares last traded at $8.20, down over 7 percent from the close.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Crash in American Electric Power (AEP) & NextEra Energy (NEE) Adds to Jitters
- Should Cirrus Logic (CRUS) Warning Resonate with Apple (AAPL) Investors?
- InterOil (IOC) Gives Up Gains
Create E-mail Alert Related Categories
Momentum Movers, Trader Talk
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
